SMP-3124LP in Adults With Advanced Solid Tumors

This study is testing a new drug called SMP-3124LP in patients with various advanced solid tumors. SMP-3124LP works by blocking certain proteins (checkpoint kinases) that cancer cells rely on to survive DNA damage from treatment, potentially making tumors more vulnerable. The study is looking at safety, dosing, and early signs of effectiveness. **You may be eligible if...** - You have an advanced, recurrent, or metastatic solid tumor that has progressed on standard therapy, including one of the following: platinum-resistant ovarian cancer, triple-negative breast cancer, anal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, or uterine serous cancer - You are in good enough health to participate (ECOG performance status of 2 or below) - Your blood counts, liver, and kidney function meet required thresholds - You agree to use effective contraception during and for 6 months after treatment **You may NOT be eligible if...** - You have previously received a cell cycle checkpoint inhibitor drug - You have brain or leptomeningeal metastases - You have significant heart problems (including ejection fraction below 45%) - You are currently on strong medications that interact with this drug (certain CYP inhibitors) - You are pregnant or breastfeeding - You have had recent cancer treatment or major surgery within 14 and 28 days, respectively Talk to your doctor to see if this trial is right for you.